Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab-IRDye800 for Optical Imaging in Pancreatic Cancer Surgery
NCT03384238Phase 2Recruiting
- Start
- Feb 2018
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in pancreatic adenocarcinoma (PDAC). Started Feb 2018; status: recruiting.
02
Drugs
panitumumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03384238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03384238.